Bibliography (25):

  1. Ozempic Is About to Be Old News

  2. It’s the Age of Ozempic. Do We Need Weight Watchers Anymore?

  3. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomized, double-blind, placebo-controlled, phase 3 trial

  4. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

  5. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomized, multicenter, placebo-controlled, phase 3 trial

  6. https://x.com/DanielJDrucker/status/1673383917888348174

  7. https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/obesity/phase-ii-clinical-trial-weight-loss-results

  8. Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial

  9. https://x.com/FattyLiverA/status/1672144869886685189

  10. https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-discontinue-development-obesity-drug-2023-06-26/

  11. Could Danuglipron Be the Next Ozempic in Pill Form?

  12. Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial

  13. https://x.com/AliceYYCheng/status/1673434959900717056

  14. https://www.nature.com/articles/s42255-023-00811-0